Texas Space Commission-supported facility expands company’s testing capacity as Venus advances its rotating detonation rocket engine technology

HOUSTON, Sept. 10, 2026 /PRNewswire/ — Venus Aerospace today officially opened its new propulsion test stand at the Houston Spaceport, adding critical infrastructure to support the continued development and maturation of its rotating detonation rocket engine technology.

Pictured from left: Clint Stephen, Houston Airport System; Congressman Morgan Luttrell; Francisco Cuellar, Houston Airport System; Norman Garza, Texas Space Commission; Sassie Duggleby, Venus Aerospace; Andrew Duggleby, Venus Aerospace; Houston City Councilmember Fred Flickinger; Houston City Councilmember Sallie Alcorn; Arturo Machuca, Ellington Airport and Houston Spaceport; and Brian Freedman, Bay Area Houston Economic Partnership.

The test stand was made possible through funding from the Texas Space Commission’s Space Exploration and Aeronautics Research Fund, part of the state’s investment in growing Texas’ aerospace and space economy. Venus completed the facility on time and on budget.

“Building and testing propulsion systems at this pace requires the right infrastructure around the technology,” said Sassie Duggleby, CEO and co-founder of Venus Aerospace. “We’re grateful to the Texas Space Commission and the State of Texas for investing alongside companies like Venus. Public investment like this helps companies move faster and keeps critical aerospace capability growing here in Texas.”

The new stand expands Venus’ ability to test at higher thrust and for longer durations, allowing the company to more closely replicate mission conditions. Together with Venus’ existing test infrastructure, it also increases overall testing capacity as the company scales integrated propulsion systems toward customer use.

Following the ribbon cutting, guests observed a live hot-fire test of a Venus rotating detonation rocket engine on the newly opened stand.

The September 10 opening brought together leaders from Venus Aerospace, the Texas Space Commission, the Houston Spaceport and Houston business and community leaders.

The opening comes during a period of rapid growth for Venus. In 2026, Venus has closed a $91 million Series B, expanded its leadership team and announced new customer and strategic relationships supporting the continued development and application of its propulsion technology. That business growth builds on significant technical progress, including the world’s first successful flight test of a high-thrust rotating detonation rocket engine in May 2025 and continued ground testing as Venus advances the technology toward customer use.

About Venus Aerospace
Venus Aerospace is building next-generation propulsion systems for defense, space, and future high-speed flight. Founded in 2020 and headquartered in Houston, Texas, Venus is developing flight-proven Rotating Detonation Rocket Engine (RDRE) technology designed to deliver greater efficiency, range, and scalability for defense and space missions. Venus’ propulsion systems are designed for domestic manufacturing and mission flexibility across national security and aerospace applications. Venus is backed by Mercury Fund, Lockheed Martin Ventures, Prime Movers Lab, Airbus Ventures, Trousdale Ventures and others. To learn more, visit www.venusaero.com.

Media Contact
Sarah Boland Heine
Sarah.Heine@venusaero.com
502-471-6186

View original content to download multimedia:https://www.prnewswire.com/news-releases/venus-aerospace-opens-new-propulsion-test-stand-at-houston-spaceport-302875839.html

SOURCE Venus Aerospace

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine.

MAIDENHEAD, United Kingdom, Sept. 11, 2026 /PRNewswire/ — CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, marking an important milestone in the evolution of influenza prevention for older adults.1

The publication follows approval of the trivalent formulation of aQIVc by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom earlier this year for adults aged 50 years and older.2 The vaccine, marketed as AUJEMFLU®, has also been approved by the European Commission for adults aged 50 years and above.

The peer-reviewed publication reports findings from a large-scale study of the first influenza vaccine to combine three proven approaches to enhancing protection in older adults: MF59® adjuvant, cell-based manufacturing, and a higher dose formulation compared to standard influenza vaccines.1,3

Each of these approaches has been used separately in influenza vaccines for many years and is supported by extensive clinical and real-world evidence. This publication provides the first large-scale evaluation of their combination within a single vaccine.1,2

Influenza remains a significant public health challenge, causing substantial illness, hospitalisations and deaths each year despite widespread vaccination programmes.4 

Older adults are particularly vulnerable because the immune system becomes less responsive with age, reducing its ability to mount a strong protective response following vaccination.5 

aQIVc combines three proven approaches to enhancing vaccine protection in older adults, with each playing a distinct and complementary role. Cell-based manufacturing helps preserve a closer match to circulating influenza strains, MF59® adjuvant strengthens, broadens and lengthens the immune response and a higher dose formulation further optimises that response.2,6,7,8

The Phase 3 randomised immunogenicity and safety study enrolled 7,699 adults aged 50 years and older across eight countries and compared aQIVc with two enhanced influenza vaccines. The study met its primary objectives and demonstrated:1

Superiority versus the adjuvanted egg-based influenza vaccine comparator across all four influenza strains and age groups assessed.Non-inferiority versus a recombinant influenza vaccine for three out of four strains in the 50+ age group and four out of four strains in those aged 65+.Immune responses that persisted throughout the influenza season.A well-tolerated safety profile. Most reactions were mild or moderate and resolved within three days.1  

The publication also reported exploratory findings of enhanced neuraminidase antibody responses versus comparators. The role of neuraminidase antibodies is an emerging area of influenza research that may contribute to reduced disease severity and broader protection beyond traditional measures of vaccine response.9

The study authors concluded that the findings support further evaluation of the vaccine and provide evidence for National Immunisation Technical Advisory Groups considering enhanced influenza vaccination strategies for older adults.1

Regulatory submissions for the trivalent formulation of aQIVc have been made in multiple markets, with introductions expected to occur through a phased approach aligned to local regulatory, policy and access pathways.

Gregg Sylvester, Chief Medical Officer and Head of Research & Development, CSL Seqirus, said:
“Publication in The Lancet Infectious Diseases is a significant milestone for CSL Seqirus and reflects decades of investment in influenza vaccine innovation.”

“These findings provide important new evidence for healthcare professionals, policy makers and immunisation advisory groups considering future influenza vaccination strategies for older adults.”

Professor Colin Russell, Chair of the European Scientific Working Group on Influenza (ESWI) and Professor of Applied Evolutionary Biology at Amsterdam University Medical Center, said:
“Influenza vaccine innovation has historically progressed through incremental advances in technology and manufacturing. What makes this study noteworthy is that it shows the potential benefit of bringing multiple proven approaches together in a single vaccine.”

“Given the continued burden of influenza-related illness, hospitalisation and death among older adults despite widespread vaccination, these findings represent an important contribution to ongoing efforts to improve protection in this vulnerable population.”

About the Phase 3 Study
The randomised, observer-blind Phase 3 immunogenicity study enrolled 7,699 adults aged 50 years and older across Canada, Denmark, Estonia, Germany, Pakistan, the Philippines, the United Kingdom and the United States. Participants received either the MF59-adjuvanted cell-derived higher dose quadrivalent vaccine, an MF59-adjuvanted egg-based quadrivalent influenza vaccine or a recombinant quadrivalent influenza vaccine. The study evaluated immunogenicity, safety and manufacturing consistency.

About aQIVc
aQIVc is an MF59-adjuvanted, cell-based higher-dose quadrivalent influenza vaccine developed for adults aged 50 years and older.  The trivalent formulation has been licensed for use in people aged 50 and above in the UK and by the European Medicines Agency where it is marketed as AUJEMFLU.®

The vaccine combines three proven approaches designed to enhance protection in older adults:

MF59 adjuvant technologyCell-based manufacturingA higher dose formulation versus standard dose influenza vaccinesEach dose contains 45 micrograms of haemagglutinin per influenza strain and 19.5 mg of MF59 adjuvant2

About CSL Seqirus
CSL Seqirus is part of CSL (ASX: CSL). As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness and response. With state-of-the-art production facilities in the US, the UK and Australia, CSL Seqirus utilises egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world. For more information about CSL Seqirus, visit www.CSL.com.

Intended Audience
This press release is issued by CSL Seqirus and is intended to provide information about our global business. Information relating to the approval status, product labels, recommendations and availability of CSL Seqirus products may vary from country to country. Please consult your local regulatory authority for information on approval status and local prescribing information.

Forward-Looking Statements
This press release may contain forward-looking statements, including statements regarding future results, performance, regulatory milestones, product availability or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on forward-looking statements.

For more information, please contact:
MEDIA CONTACT 
Alex Kiefer
Alex.Kiefer@Seqirus.com
Director International & Pandemic Communications, CSL Seqirus 

GL-aTIVc-26-0011

References

1 Essink BJ, Vermeulen W, Andrade C, Mazur M, de Rooij R, Heijnen E, et al. Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial. Lancet Infect Dis. In press 2026. Volume 26. September 2026.  THELANCETID-D-26-00167R3.
2 Aujemflu suspension for injection in pre-filled syringe: summary of product characteristics [Internet]. Maidenhead: Seqirus UK Limited; 4 June 2026 (PL 47991/0020). Available from: https://www.medicines.org.uk/emc/product/102343/smpc cited 2026 Aug 2.
3 Ashraf M, Boivin W, Nguyen-Van-Tam JS, Nolan T, Stein AN, Russell CA. Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness. Expert Rev Vaccines. 2026;25(1):2667732. doi:10.1080/14760584.2026.2667732.
4 World Health Organization. Influenza (seasonal): fact sheet [Internet]. Geneva: WHO; 28 February 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)  cited 2026 Aug 28.
5 Cadar AN, Martin DE, Bartley JM. Targeting the hallmarks of aging to improve influenza vaccine responses in older adults. Immun Ageing. 2023;20:23. doi:10.1186/s12979-023-00348-6.
6 Essink BJ, Vermeulen W, Andrade C, de Rooij R, Isakov L, Casula D, et al. A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older. Vaccine. 2025;51:126791. doi:10.1016/j.vaccine.2025.126791.
7 de Looze F, Essink BJ, van Boxmeer J, Andrade C, de Rooij R, Casula D, et al. Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: combined results of randomised, controlled dose-finding and dose-confirmation studies. Vaccine. 2026;79:128436. doi:10.1016/j.vaccine.2026.128436.
8 Ashraf M, Stein AN, Youhanna J, Rockman S, McMahon M, McGovern I, et al. The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness. Vaccine. 2025;62:127393. doi:10.1016/j.vaccine.2025.127393.
9 Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis. 2015;212(8):1191-99. doi:10.1093/infdis/jiv195.

View original content:https://www.prnewswire.com/apac/news-releases/lancet-publication-marks-important-advance-in-influenza-prevention-for-older-adults-302875822.html

SOURCE CSL Seqirus

SHENZHEN, China, Sept. 10, 2026 /PRNewswire/ — Tencent Music Entertainment Group (“TME,” or the “Company”) (NYSE: TME and HKEX: 1698), the leading all-in-one music and audio entertainment platform in China, today announced the closing of its public offering of US$1,000 million aggregate principal amount of senior unsecured notes consisting of US$500 million of 5.050% notes due 2031 and US$500 million of 5.650% notes due 2036. The notes have been registered under the U.S. Securities Act of 1933, as amended, and are expected to be listed on The Stock Exchange of Hong Kong Limited on September 11, 2026.

The Company received net proceeds from the offering of approximately US$991.9 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the offering for general corporate purposes, including refinancing of offshore indebtedness and share repurchases.

The joint bookrunners of the offering are J.P. Morgan Securities LLC, Goldman Sachs (Asia) L.L.C. and The Hongkong and Shanghai Banking Corporation Limited. The joint lead managers of the offering are UBS AG Hong Kong Branch, Bank of China Limited and MUFG Securities Asia Limited.

The Company has an automatic shelf registration statement on Form F-3 (including a base prospectus) on file with the U.S. Securities and Exchange Commission (the “SEC”) and has filed the related prospectus supplement with the SEC for the offering of the notes. The offering is being made only by means of the prospectus supplement and accompanying base prospectus. Before you invest, you should read the prospectus supplement and accompanying base prospectus and other documents that the Company has filed with the SEC for more complete information about the Company and the offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send an investor the prospectus if the investor requests it by calling J.P. Morgan Securities LLC located at 270 Park Ave, New York, NY 10017, USA at +1-212-834-4533, Goldman Sachs & Co. LLC, an affiliate of Goldman Sachs (Asia) L.L.C., located at 200 West Street, New York, NY 10282, USA at +1-866-471-2526 or The Hongkong and Shanghai Banking Corporation Limited, located at L17, HSBC Main Building, 1 Queen’s Road Central, Hong Kong at +1-866-811-8049.

This announcement is not an offer of the securities for sale in the United States and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities referred to herein have not been and will not be registered under the applicable securities laws of any jurisdiction outside of the United States.

About Tencent Music Entertainment

Tencent Music Entertainment Group (NYSE: TME and HKEX: 1698) is the leading all-in-one music and audio entertainment platform in China, operating the country’s highly popular and innovative music and audio apps: QQ Music, Kugou Music, Kuwo Music, WeSing and Ximalaya. TME’s mission is to create endless possibilities with music and technology. Powered by its content-and-platform dual-engine strategy, TME’s expansive offerings extend the value of IP beyond online streaming into offline concerts, artist merchandise, and other IP-centric experiences. TME continuously innovates to deliver a seamless experience where users can discover, listen, sing, watch, perform, and connect across diverse scenarios, while unlocking the enduring value of music and audio IP. For more information, please visit ir.tencentmusic.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law.

Investor Relations Contact
Tencent Music Entertainment Group
ir@tencentmusic.com
+86 (755) 8601-3388 ext. 885034

View original content:https://www.prnewswire.com/news-releases/tencent-music-entertainment-group-announces-closing-of-us1-000-million-notes-offering-302875462.html

SOURCE Tencent Music Entertainment Group